Ascelia Pharma AB (publ) (ticker: ACE) today announced that results from the Orviglance® Food Effect Study have been accepted as an oral presentation at the world’s largest radiology conference, RSNA. The conference will be held November 27 – December 1 in Chicago, Illinois.
The Food Effect Study evaluates the effect of food intake on absorption and signal intensity of Orviglance. The results, originally announced in May 2022, showed that intake of a light meal prior to Orviglance administration provides similar image MRI enhancement of the liver compared to a fasting condition. In line with previous studies, the data also confirmed robust image enhancement of the liver after Orviglance administration compared to an MRI image without a contrast agent.
“We are very pleased that the study has been selected as an oral paper presentation at the prestigious radiology conference RSNA. Avoiding a fasting condition improves the convenience for patients and ease in the administration of Orviglance in clinical practice. The results further support our previous findings on the ability to provide image enhancement to MRI scans with Orviglance,” said Carl Bjartmar, Chief Medical Officer of Ascelia Pharma.
Title of presentation: Effect of Food Intake on Pharmacodynamics of A Novel Oral Liver-specific ContrastAgent: Orviglance (Manganese Chloride Tetrahydrate)
Timing of presentation: November 30, 3.00pm local time Chicago.